Drugs / PRT7732
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06560645 | Nov 2024 → Jan 2026 | esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, gastric squamous cell carcinoma +3 | Prelude Therapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-09 | Prelude Therapeutics | Results Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting preludetx.com ↗
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-09 | Prelude Therapeutics | Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting preludetx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT7732 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06560645 ↗ |
| Modality | Other / unclassified | “PRT7732, an oral SMARCA2 degrader” NCT06560645 ↗ |
| Route | Oral | “PRT7732 is administered as an oral capsule once daily” NCT06560645 ↗ |
| Target | SMARCA2 | “PRT7732, an oral SMARCA2 degrader” NCT06560645 ↗ |